Bausch Health Posts Strong Q2 2026 Growth, Raises Full-Year Guidance
Event summary
- Bausch Health reported Q2 2026 revenues of $2.85 billion, up 13% year-over-year.
- Adjusted EBITDA attributable to Bausch Health rose 28% to $1.075 billion.
- The company raised its full-year revenue and Adjusted EBITDA guidance.
- Cash provided by operating activities increased 132% to $671 million.
The big picture
Bausch Health's strong Q2 2026 results reflect disciplined execution and portfolio strength. The company's focus on reducing debt and improving financial flexibility positions it well in a competitive pharmaceutical landscape. The raised guidance underscores confidence in sustained performance, though external factors like tariffs remain a wildcard.
What we're watching
- Revenue Growth Sustainability
- Whether Bausch Health can maintain its strong revenue growth trajectory, particularly in the Salix and Solta Medical segments.
- Debt Management
- The company's ability to reduce net debt further and improve its balance sheet strength.
- Strategic Priorities
- How Bausch Health will unlock shareholder value through potential asset maximization, including the separation of its eye health business.
Related topics